Expanding Genetic Access for Prostate Cancer Survivors (NCT07618520)
Expanding Genetic Access and Guided Education for Prostate Cancer Survivors
🩺 Plain-English Summary (8th-Grade Level)
The goal of this study is to increase genetic education and genetic testing for hereditary cancer risk among prostate cancer survivors. The study will: Test the effectiveness of a digital guide (DG+) vs. print guide (Print+) vs. enhanced usual care (EUC) on engagement in genetic education and uptake of genetic testing. Evaluate the impact of the DG+ vs. Print+ vs. EUC on the process that participants use to make decisions and evaluate effects on well-being (also called psychosocial outcomes). Explore the ways (methods) that influence how participants experience the intervention. The main questions this study aims to answer are: which group - the digital guide (DG+) group, print (Print+) group or the EUC group - is more likely to request genetic testing and which group is more likely to get (engage with) genetic education. Participants will be randomly assigned to either the digital guide (DG+) group, the print guide (Print+) group or EUC group. Each group will receive genetic education and have an opportunity to request genetic testing. Researchers will compare the three groups to determine which is most most likely to complete genetic testing (GT) and which group engages more with genetic education.
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (9 items) and avoid the listed exclusions (5 items).
Location: Georgetown University Medical Center/Lombardi Comprehensive Cancer Center — Washington D.C., District of Columbia
Age range: 18 Years to 80 Years
🧪 Interventions in This Study
- Print Genetic Education Guide (BEHAVIORAL)
- Digital Guide Genetic Education Guide (BEHAVIORAL)
- Enhanced Usual Care (BEHAVIORAL)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion Criteria:
- Do not speak English
- Unable to access the Internet
- Have previously undergone germline genetic testing for hereditary cancer risk or previously had genetic counseling (GC) and declined genetic testing (GT)
- Are unable to provide informed consent
🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
📍 All Participating Trial Locations (2 Sites)
- Georgetown University Medical Center/Lombardi Comprehensive Cancer Center — Washington D.C., District of Columbia
- Rutgers University/Rutgers Cancer Institute — New Brunswick, New Jersey
📞 Contact the Study Coordinator
Phone: (202) 687-0185
Email: schwartm@georgetown.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Prostate Cancer Patients
- Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC — Madison, Wisconsin
- A Dose Optimization Study of Enzalutamide in Elderly Patients With Advanced Prostate Cancer — Toronto, Ontario
- Radiation Therapy Approaches for People With Prostate Cancer — Basking Ridge, New Jersey
Explore by condition: All Prostate Cancer Patients clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.